These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17395094)

  • 1. Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies.
    Dixit R; Boelsterli UA
    Drug Discov Today; 2007 Apr; 12(7-8):336-42. PubMed ID: 17395094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical predictors of clinical safety: opportunities for improvement.
    Sistare FD; DeGeorge JJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunostimulatory antibodies: challenging the drug testing paradigm.
    Bhogal N; Combes R
    Toxicol In Vitro; 2007 Oct; 21(7):1227-32. PubMed ID: 17434714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems.
    Dixit R; Coats S
    IDrugs; 2009 Feb; 12(2):103-8. PubMed ID: 19204884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing human biologicals in animal host resistance models.
    Burleson GR; Burleson FG
    J Immunotoxicol; 2008 Jan; 5(1):23-31. PubMed ID: 18382855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical testing for teratogenicity and developmental toxicity: methods and limitations.
    Barrow PC
    Therapie; 2002; 57(2):109-14. PubMed ID: 12185956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
    Powley MW; Frederick CB; Sistare FD; DeGeorge JJ
    Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human experimental pain models in drug development: translational pain research.
    Arendt-Nielsen L; Curatolo M; Drewes A
    Curr Opin Investig Drugs; 2007 Jan; 8(1):41-53. PubMed ID: 17263184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery.
    Petersen TK
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):104-15. PubMed ID: 16918710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
    Muller PY; Brennan FR
    Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical models of arthritic disease in non-human primates.
    Vierboom MP; Jonker M; Tak PP; 't Hart BA
    Drug Discov Today; 2007 Apr; 12(7-8):327-35. PubMed ID: 17395093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do preclinical testing strategies help predict human hepatotoxic potentials?
    Peters TS
    Toxicol Pathol; 2005; 33(1):146-54. PubMed ID: 15805066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Techniques: magnetic resonance imaging of the lung provides potential for non-invasive preclinical evaluation of drugs.
    Beckmann N; Tigani B; Mazzoni L; Fozard JR
    Trends Pharmacol Sci; 2003 Oct; 24(10):550-4. PubMed ID: 14559408
    [No Abstract]   [Full Text] [Related]  

  • 16. The impact of molecular biology on drug discovery.
    Belfield GP; Delaney SJ
    Biochem Soc Trans; 2006 Apr; 34(Pt 2):313-6. PubMed ID: 16545102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Animal models of idiosyncratic drug reactions.
    Shenton JM; Chen J; Uetrecht JP
    Chem Biol Interact; 2004 Nov; 150(1):53-70. PubMed ID: 15522261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ensuring the quality, potency and safety of vaccines during preclinical development.
    Lebron JA; Wolf JJ; Kaplanski CV; Ledwith BJ
    Expert Rev Vaccines; 2005 Dec; 4(6):855-66. PubMed ID: 16372881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The adult human brain in preclinical drug development.
    Dragunow M
    Nat Rev Drug Discov; 2008 Aug; 7(8):659-66. PubMed ID: 18617887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring.
    Muller PY; Dieterle F
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1023-38. PubMed ID: 19611406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.